Integrating Continuous Glucose Monitoring Into Diabetes Care: Meaningful Engagement for Improved Patient Outcomes

Provided by Clinical Care Options, LLC in collaboration with the University of Virginia, Endocrine Society, and RealCME

Acknowledgment

This activity is supported by educational grants from Abbott Diabetes. 

Learning Objectives

Upon completion of this activity, learners should be able to:

• Describe guideline recommendations for incorporating CGM in persons with diabetes on oral agents as well as injectables 
• Summarize the benefits of CGM regarding reducing postprandial hyperglycemia, increasing time in range, improving A1C, and reducing hypoglycemia risk 
• Explore strategies to overcome clinician/patient barriers and, through multiprofessional small group interactions, improve adoption of CGM devices in community practices 

Disclosure of Conflicts of Interest

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty

Ananda Basu, MD, FRCP
Harrison Professor of Medicine
Clinician-Investigator
Division of Endocrinology
Center for Diabetes Technology
Director, Diabetes Technology Program
University of Virginia, Charlottesville, VA

Rita Basu, MD
Professor of Medicine
Division of Endocrinology,
Clinical Education Director of Center for Diabetes Technology
Chair Institutional Review Board –Health Sciences Research
University of Virginia School of Medicine, USA

Rodolfo J. Galindo, MD, FACE
Associate Professor of Medicine
Investigator, Center for Diabetes & Metabolism Research
Emory University Hospital Midtown
Medical Chair, Hospital Diabetes Taskforce
Emory Healthcare System

Elyse Marriner BSN, RN, CDCES
Registered Nurse
Endocrinology Pantops
University Physicians Group
Charlottesville, Virginia

Roger Mazze, PhD
Director, AGP Clinical Academy, Portsmouth University Hospitals, NHST, UK
Visiting Professorship, Nanjing Medical University,
Nanjing, China

Viral Shah, MD
Associate Professor of Medicine and Pediatrics
Barbara Davis Center for Diabetes
University of Colorado
Aurora, Colorado

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Ananda Basu, MD, FRCP, has disclosed that he has received consulting fees from Zealand.

Rita Basu, MD has disclosed that she has received consulting fees from Sparrow Pharmaceuticals, and funds for research support from Astra Zeneca and Abbott Diabetes Care. 

Rodolfo J. Galindo, MD, FACE has disclosed that he has received funds for research support from Dexcom, Eli Lilly, and Novo Nordisk.

Elyse Marriner, BSN, RN, CDCES has no relevant conflicts of interest to report.

Roger S. Mazze, PhD has no relevant conflicts of interest to report.

Viral N Shah, MD has disclosed that he has received consulting fees from Dexcom and Sanofi, and funds for research support from Dexcom, Eli Lilly, Insulet, Novo Nordisk, and Sanofi. 

Staff

CCO staff and planners have no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Target Audience

This program is intended for healthcare practitioners who treat patients with diabetes, including endocrinologists, internists, primary care physicians, pediatricians, obstetricians, and advanced practice providers. 

Goal

The goal of this CME/CE-certified curriculum, “Integrating Continuous Glucose Monitoring Into Diabetes Care: Meaningful Engagement for Improved Patient Outcomes,” is to establish impactful small group interactions between members of the diabetes care team that will, through a variety of collaborative educational experiences, help them to fully integrate CGM into daily practice.

Accreditation Information

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Education

CCO designates this other activity, Gather-ed, for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this activity is 3.0 contact hours.

• Program Medium
• This program has been made available online.

• Instructions for Credit
• Participation in this activity should be completed in approximately 3.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 20, 2022, through June 20, 2023:

1. Register online at https://www.realcme.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity.
4. To claim the maximum amount of credit available, you must complete all of the following:

• Completion of baseline/final assessment: 0.5 credit hours
• Completion of all modules: 1 credit hour
• Live Group Discussion 1: 0.5 credit hours
• Live Group Discussion 2: 0.5 credit hours
• Completion of group task 1: 0.25 credit hours
• Completion of group task 2: 0.25 credit hours